Literature DB >> 15542427

Focus on multiple myeloma.

Constantine S Mitsiades1, Nicholas Mitsiades, Nikhil C Munshi, Kenneth C Anderson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15542427     DOI： 10.1016/j.ccr.2004.10.020

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


× No keyword cloud information.
  46 in total

1.  Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells.

Authors:  Mu Hao; Li Zhang; Gang An; Weiwei Sui; Zhen Yu; Dehui Zou; Yan Xu; Hong Chang; Lugui Qiu
Journal:  J Hematol Oncol       Date:  2011-09-22       Impact factor: 17.388

Review 2.  Immunotherapy strategies for multiple myeloma: the present and the future.

Authors:  Frederick L Locke; Taiga Nishihori; Melissa Alsina; Mohamed A Kharfan-Dabaja
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

3.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

4.  The confabulatory semiotics: naming and cognition of diseases by pathologists.

Authors:  Alejandro Peralta Soler; Juana Soler de Peralta
Journal:  Med Health Care Philos       Date:  2005

5.  Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.

Authors:  B Belinda Ding; J Jessica Yu; Raymond Y-L Yu; Lourdes M Mendez; Rita Shaknovich; Yonghui Zhang; Giorgio Cattoretti; B Hilda Ye
Journal:  Blood       Date:  2007-10-19       Impact factor: 22.113

6.  Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

Authors:  Teru Hideshima; Laurence Catley; Hiroshi Yasui; Kenji Ishitsuka; Noopur Raje; Constantine Mitsiades; Klaus Podar; Nikhil C Munshi; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

Review 7.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

8.  IRF4 addiction in multiple myeloma.

Authors:  Arthur L Shaffer; N C Tolga Emre; Laurence Lamy; Vu N Ngo; George Wright; Wenming Xiao; John Powell; Sandeep Dave; Xin Yu; Hong Zhao; Yuxin Zeng; Bangzheng Chen; Joshua Epstein; Louis M Staudt
Journal:  Nature       Date:  2008-06-22       Impact factor: 49.962

9.  The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.

Authors:  James J Driscoll; Dheeraj Pelluru; Konstantinos Lefkimmiatis; Mariateresa Fulciniti; Rao H Prabhala; Philip R Greipp; Bart Barlogie; Yu-Tzu Tai; Kenneth C Anderson; John D Shaughnessy; Christina M Annunziata; Nikhil C Munshi
Journal:  Blood       Date:  2009-11-30       Impact factor: 22.113

10.  Correlation of high-resolution X-ray micro-computed tomography with bioluminescence imaging of multiple myeloma growth in a xenograft mouse model.

Authors:  Andrei A Postnov; Henk Rozemuller; Viviene Verwey; Henk Lokhorst; Nora De Clerck; Anton C Martens
Journal:  Calcif Tissue Int       Date:  2009-10-09       Impact factor: 4.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.